Cancer Genomics and Classification of Leukemia
How genetic and routine clinical data can describe biologically meaningful groups of acute leukemia, with an emphasis on AML and large collaborative cohorts.
Research
What the group is working on
Projects move from exploring to validating to published.
Pillars
Transplant outcomes and complications
Data-driven analysis of graft-versus-host disease, infection, immune reconstitution and related complications after hematopoietic cell transplantation.
Cancer Health Disparities and AI
Methods that start from data already generated in hematology care — laboratory values, pathology text, transfusion records — and ask what can be learned without new specialized assays.
Data Science Methods and Tools
Public aGVHD grading tools and code, including gvhd.online, so methods can be inspected beyond a single paper.
Data-driven decision support
Published tools for clinical decisions in hematology care, including data-driven aGVHD grading.
Methods development
Public tools and code. The aGVHD calculator belongs with the 2023 Nature Communications grading paper.
Data-driven aGVHD grading · gvhd.online · All public software
Current research
Programs with a public footprint in papers, abstracts or tools.
Validating
HARMONY AML classification
Within the HARMONY Alliance, the group is developing and internationally validating an unsupervised genomic classification of AML. This work has been presented in the EHA 2025 plenary session and as an ASH 2025 oral abstract. It is not yet represented here as a peer-reviewed article.
Cancer genomics and leukemia classification · HARMONY Alliance
Explore projectPublished
aGVHD grading
The group led a multi-center effort to rebuild acute GVHD grading from organ-stage data. The 2023 Nature Communications paper is accompanied by a public calculator (gvhd.online) and source code.
Transplant complications · Multi-center German transplant centers as described in the paper
Explore projectRecently published
Leukemia laboratory AI
A 2026 Nature Communications paper reports international testing and refinement of algorithms that predict acute leukemia subtypes from routine laboratory data. Related commentary appears in Lancet Digital Health (2024).
Cancer health disparities and AI · International hospital network described in the paper
Explore projectPublished
CMV and immune reconstitution
A series of papers from the group examines CMV kinetics, immune reconstitution and relapse risk after HCT, including work led by Saskia Leserer.
Transplant complications · Clinical HCT cohorts as described in the papers
Explore projectActive
AI in transplant care
The group writes and speaks about how AI can support transplant care and complication management, including a 2025 review with lab co-authors.
Cancer health disparities and AI
Explore projectActive
PathRoClus
The lab site lists the PathRoClus Consortium, supported by EHA. Public materials describe a federated platform for hematological malignancies.
Cancer genomics and leukemia classification · PATHroclus consortium
Explore projectActive
HARMONY MRD
Supported by the José Carreras Leukemia Foundation (DJCLS), this program uses hierarchical Dirichlet mixture models and other data-driven methods to investigate measurable residual disease in AML. It is a collaboration with HARMONY / IBSAL in Salamanca and FIDIS in Santiago de Compostela.
Cancer genomics and leukemia classification · HARMONY Alliance
Explore projectActive
ATLG pharmacokinetics
Building on earlier work on ATLG dosing after unrelated HCT, the group has presented further pharmacokinetics modeling toward individualized dosing. Public description here is limited to conference-abstract level; no unpublished results are given.
Transplant complications
Explore projectEarlier programs
Published
XplOit
XplOit was a BMBF-funded platform for integrating clinical data to support predictive modeling, including in allogeneic stem cell transplantation.
Cancer health disparities and AI · XplOit consortium
Explore project